Comparision Of Overall Survival For Non-small Cell Lung Cancer Patients
Links shared publicly online about this topic.
- 1,126total visits
Comparision Of Overall Survival For Non-small Cell Lung Cancer Patients
View full resource at medicalnewstoday.com
Tags: Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Lung
Most Recently Shared on June 1, 2010 at 4:39 pm By:
Comparision Of Overall Survival For Non-small Cell Lung Cancer Patients: There's debate about the best treatment a... http://mnt.to/f/3Djk
Also Shared By:
Symposier - Dr. Belani Discusses NSCLC Adjuvant Therapy
symposier.com — “Uploaded and shared in Youtube by: OncLiveTV — Chandra P. Belani, MD, Deputy Director, Penn State Hershey Cancer Institute, Miriam Beckner Distinguished Professor of Medicine, Penn State Hershey Medical Center & College of Medicine, discusses recent changes to adjuvant therapy for non-small cell lung cancer (NSCLC). Adjuvant therapy is the current standard of care for patients with resectable NSCLC. Various trials have suggested that the absolute improvement in overall survival from adjuvant tre” View full resource at symposier.com
Most Recently Shared on January 4, 2012 at 5:56 pm By:
Recent changes to adjuvant therapy for non-small cell lung cancer (NSCLC). http://t.co/maBnxPAJ
Symposier - SABR Ups Survival in Early Lung Cancer
symposier.com — “Uploaded and shared in Youtube by: ElsGlobalMedicalNews — Wide adoption of stereotactic ablative radiation as radiotherapy for elderly patients with stage 1 non-small cell lung cancer in the Netherlands produced a dramatic rise in overall survival during the 2000s. Dr. Suresh Senan discusses the results. See the related story at http://tinyurl.com/3cvnl4n” View full resource at symposier.com
Most Recently Shared on August 23, 2011 at 8:04 pm By:
SABR Boost survival in Stage I NSCLC, Dutch data document SABR efficacy for elderly patients. http://t.co/D8ooqeX
Vandetanib Superior to Placebo in Progression-Free Survival in NSCLC; No Benefit in Overall Survival - ONA
oncologynurseadvisor.com — “Vandetanib maintenance therapy demonstrated longer progression-free survival rates in patients with recurrent non-small cell lung cancer compared to those receiving placebo as reported by Joseph Aisner, MD, of the Cancer Institute of New Jersey, New Brunswick, and colleagues at the American Society of Clinical Oncology’s 2011 Annual Meeting.” View full resource at oncologynurseadvisor.com
Most Recently Shared on June 4, 2011 at 10:04 pm By:
OncologyNurseAdvisor Medical Education, Medical Publisher, Oncology, and Nursing
Vandetanib Superior to Placebo in Progression-Free Survival in NSCLC; No Benefit in Overall… http://goo.gl/fb/mdMhB
Vandetanib Superior to Placebo in Progression-Free Survival in NSCLC; No Benefit in Overall Survival - MPR
empr.com — “Vandetanib maintenance therapy demonstrated longer progression-free survival rates in patients with recurrent non-small cell lung cancer compared to those receiving placebo as reported by Joseph Aisner, MD, of the Cancer Institute of New Jersey, New Brunswick, and colleagues at the American Society of Clinical Oncology’s 2011 Annual Meeting.” View full resource at empr.com
Most Recently Shared on June 4, 2011 at 10:00 pm By:
MPR News: Vandetanib Superior to Placebo in Progression-Free Survival in NSCLC; No Benefit in Overall Survival: ... http://bit.ly/jx2opF
MedWire News - Oncology - NSCLC survival not improved by addition of bevacizumab to erlotinib
medwire-news.md — “MedWire News Addition of bevacizumab to erlotinib does not improve overall survival in patients with recurrent or refractory non-small-cell lung cancer after first-line treatment failure, results of an international, phase III clinical trial show. MedWire News” View full resource at medwire-news.md
Most Recently Shared on June 1, 2011 at 9:24 am By:
NSCLC survival not improved by addition of bevacizumab to erlotinib http://bit.ly/jxDVeA #oncology
Oncology Article | Survival Vascular Endothelial Growth Factors Carcinoma, Non-Small-Cell Lung Lung Neoplasms
mdlinx.com — “Posttreatment plasma VEGF levels may be associated with the overall survival of patients with advanced non-small cell lung cancer treated with bevacizumab plus chemotherapy” View full resource at mdlinx.com
Most Recently Shared on April 8, 2011 at 10:22 am By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Posttreatment plasma VEGF levels may be associated with the overall survival of patients with advanced... http://bit.ly/fK6eQX #oncology
Medical News: CTS: Combo Fails to Raise Survival in Advanced Lung CA - in Meeting Coverage, CTS from MedPage Today
medpagetoday.com — “CHICAGO -- Combining sunitinib (Sutent) with erlotinib (Tarceva) did not improve overall survival in patients with advanced non-small cell lung cancer (NSCLC) compared with erlotinib alone, a phase II” View full resource at medpagetoday.com
Most Recently Shared on December 14, 2010 at 5:13 pm By:
CTS: Combo Fails to Raise Survival in Advanced Lung CA (CME/CE) http://bit.ly/gxd1u4
Final results from landmark trial confirm survival benefits of EGFR mutations in lung cancer
news-medical.net — “Mature results from a landmark Phase-III trial have confirmed that patients with EGFR mutation-positive advanced non-small cell lung cancer have better overall survival when treated with gefitinib or chemotherapy than patients whose tumors do not carry such mutations.” View full resource at news-medical.net
Most Recently Shared on October 12, 2010 at 3:51 am By:
Lung Cancer News: Final results from landmark trial confirm survival benefits of EGFR mutations in lung cancer: Ma... http://bit.ly/9UgCb2
Novocure Reports Data Showing TTF Therapy in Combination With Chemotherapy Has the Potential to Increase Overall Survival for Patients With Advanced Non-Small Cell Lung Cancer - Drugs.com MedNews
drugs.com — “Data Presented Today at the 35th European Society for Medical Oncology Congress Novocure reported today that patients with advanced non-small cell lung cancer (” View full resource at drugs.com
Most Recently Shared on October 11, 2010 at 11:06 pm By:
Drugs and Devices OW OW Health
Novocure Reports Data Showing TTF Therapy in Combination With Chemotherapy Has the Potential to Increase Over... http://bit.ly/9qaMVb #drug
Medical News: ESMO: IPASS Data Show No Survival Benefit for Gefitinib - in Meeting Coverage, ESMO from MedPage Today
medpagetoday.com — “MILAN -- Final results of the IRESSA Ran Asia Study (IPASS) failed to show any difference in overall survival between patients with advanced non-small cell lung cancer treated with gefitinib (Iressa)” View full resource at medpagetoday.com
Most Recently Shared on October 11, 2010 at 9:43 pm By:
Drugs and Devices OW OW Health
ESMO: IPASS Data Show No Survival Benefit for Gefitinib: MILAN -- Final results of the IRESSA Ran Asia Study ... http://bit.ly/aYC2uL #drug
ESMO: IPASS Data Show No Survival Benefit for Gefitinib (CME/CE) - QualityPoint Technologies
qualitypointtech.net — “MILAN (MedPage Today) -- Final results of the IRESSA Ran Asia Study (IPASS) failed to show any difference in overall survival between patients with advanced non-small cell lung cancer treated with gefitinib (Iressa) or carboplatin (Paraplatin) and paclitaxel (Taxol) chemotherapy, researchers said here.” View full resource at qualitypointtech.net
Most Recently Shared on October 11, 2010 at 9:24 pm By:
ESMO: IPASS Data Show No Survival Benefit for Gefitinib (CME/CE): MILAN (MedPage Today) -- Final results of the IR... http://bit.ly/dCHVOt
Medical News: ESMO: IPASS Data Show No Survival Benefit for Gefitinib - in Meeting Coverage, ESMO from MedPage Today
medpagetoday.com — “MILAN -- Final results of the IRESSA Ran Asia Study (IPASS) failed to show any difference in overall survival between patients with advanced non-small cell lung cancer treated with gefitinib (Iressa)” View full resource at medpagetoday.com
Most Recently Shared on October 11, 2010 at 8:46 pm By:
ESMO: IPASS Data Show No Survival Benefit for Gefitinib (CME/CE) http://bit.ly/bMdlDv
Stutent Did Not Improve Overall Survival In Patients With Previously Treated Advanced Non-small Cell Lung Cancer - QualityPoint Technologies
qualitypointtech.net — “The SUN 1087 trial of Stutent (sunitinib malate) combined with erlotinib versus just elrotinib did not improve overall survival in patients with previously treated NSCLC (non-small cell lung cancer), Pfizer Inc. informs. However, the combination therapy did demonstrate a significant improvement in progression free survival.. The study's primary endpoint was overall survival, while progression-free survival was a secondary endpoint. Trial participators and clinicians reported no unexpected types ” View full resource at qualitypointtech.net
Most Recently Shared on August 25, 2010 at 2:12 am By:
Stutent Did Not Improve Overall Survival In Patients With Previously Treated Advanced Non-small Cell Lung Cancer: ... http://bit.ly/9ZiuGW
Topline Results From Phase 3 Trial Of Sunitinib With Erlotinib In Advanced Non-Small Cell Lung Cancer (NSCLC) - QualityPoint Technologies
qualitypointtech.net — “Pfizer Inc. (NYSE :PFE) announced that the SUN 1087 trial of sunitinib in combination with erlotinib versus erlotinib demonstrated a statistically significant improvement in Progression-Free but not in Overall Survival in patients with previously treated advanced non-small cell lung cancer (NSCLC). Overall survival was the primary endpoint of the study and Progression-Free Survival was a secondary endpoint of the study. No new or unexpected types of adverse events were observed in the study...” View full resource at qualitypointtech.net
Most Recently Shared on August 24, 2010 at 1:03 pm By:
Topline Results From Phase 3 Trial Of Sunitinib With Erlotinib In Advanced Non-Small Cell Lung Cancer (NSCLC): Pfi... http://bit.ly/dgKbto
Pfizer reports Progression-Free survival in SUN 1087 combination trial of sunitinib with erlotinib for NSCLC
news-medical.net — “Pfizer Inc. announced today that the SUN 1087 trial of sunitinib in combination with erlotinib versus erlotinib demonstrated a statistically significant improvement in Progression-Free but not in Overall Survival in patients with previously treated advanced non-small cell lung cancer (NSCLC).” View full resource at news-medical.net
Most Recently Shared on August 24, 2010 at 5:14 am By:
Lung Cancer News: Pfizer reports Progression-Free survival in SUN 1087 combination trial of sunitinib with erlotin... http://bit.ly/dA8iII
Advertisement
MNT Lung Cancer
@mnt_lungcancer
Comparision Of Overall Survival For Non-small Cell Lung Cancer Patients http://mnt.to/3Djk #lungcancer
1 year ago...